Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Global Trends, Market Share, Industry Size, Growth, Opportunities and Market Forecast – 2022 to 2028

The Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market is expected to witness market growth at a CAGR of 25% during the forecast period of 2022 to 2028.

Tranthyretin amyloidosis (ATTR) is a rare, progressive and severe disease. Transthyretin amyloid cardiomyopathy (ATTR-CM) is a type of transthyretin amyloidosis (ATTR) that affects the heart and causes restrictive cardiomyopathy and progressive heart failure. It is a rare, life-threatening condition that is usually underdiagnosed. The increasing incidence of transthyretin amyloid cardiomyopathy (ATTR-CM) among the aging population is expected to drive the growth of the transthyretin amyloid cardiomyopathy (ATTR-CM) market. For example, according to an article published by the World Heart Federation in August 2019, wild-type transthyretin amyloid cardiomyopathy (ATTR-CM) is the more common type and usually affects men after the age of 60. Hereditary transthyretin amyloidosis (hATTR) occurs in people in their 50s and 60s.

Market Segments

By Type

• Hereditary Transthyretin Amyloidosis (hATTR)
• Wild Type Transthyretin Amyloidosis (wtATTR)

By Drug Type

• Transthyretin Stabilizers
• Nonsteroidal anti-inflammatory drugs (NSAID)
• RNAi therapy

Key Players

• Pfizer Inc
• GlaxoSmithKline Plc.
• Eidos Therapeutics
• Ionis Pharmaceuticals, Inc.
• Alnylam Pharmaceuticals
• Prothena Corporation plc
• Intellia Therapeutics, Inc.
• Corino Therapeutics, Inc.

Scope of the Report

The research study analyzes the global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment industry from 360-degree analysis of the market thoroughly delivering insights into the market for better business decisions, considering multiple aspects some of which are listed below as:

Recent Developments

o Market Overview and growth analysis
o Import and Export Overview
o Volume Analysis
o Current Market Trends and Future Outlook
o Market Opportunistic and Attractive Investment Segment

Geographic Coverage

o North America Market Size and/or Volume
o Latin America Market Size and/or Volume
o Europe Market Size and/or Volume
o Asia-Pacific Market Size and/or Volume
o Rest of the world Market Size and/or Volume

Key Questions Answered by Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Report

1. What was the Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market size in 2020 and 2021; what are the estimated growth trends and market forecast (2022-2028).

2. What will be the CAGR of Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market during the forecast period (2022-2028)?
3. Which segments (product type/applications/end-user) were most attractive for investments in 2022? How these segments are expected to grow during the forecast period (2022-2028).
4. Which manufacturer/vendor/players in the Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market was the market leader in 2020?
5. Overview on the existing product portfolio, products in the pipeline, and strategic initiatives taken by key vendors in the market.